Genomic Vision Expands its Senior Management Team through a Number of Strategic Recruitments
11 Janvier 2016 - 6:00PM
Business Wire
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a
molecular diagnostics company specializing in the development of
diagnostic tests for genetic diseases and cancers based on
molecular combing technology, today announces three strategic
appointments to its senior management team.
M. Stephane Altaba, PhD., is appointed Vice-President
Corporate DevelopmentWith a PhD. in biotechnology from the
Ecole Nationale Supérieure d'Agronomie et des Industries
Alimentaires (ENSAIA) and an MBA in Management (ESCP Europe),
Stephane Altaba (50) has over 20 years of experience in strategic
positions in pharmaceutical companies. Before joining Genomic
Vision, Stephane Altaba was Vice-President Corporate Business
Development at Nordic Pharma Group (2006-2015). Prior to that, he
was Director Corporate Licenses at Sanofi, where he began his
career as a research scientist in 1994 after completing his
postdoctoral studies at Riken, the largest life sciences research
institution in Japan.
M. Camille Chypre, PhD., is appointed Vice-President
R&DPhD. in cellular and molecular biology (University of
Strasbourg) and biochemical engineer (INSA Lyon), Camille Chypre
(50) has over 25 years of experience in positions of responsibility
in major international diagnosis companies such as Canadian company
DiagnoCure (1997-2005) and American company BioRad (2005-2013).
Before joining Genomic Vision, Camille Chypre was Executive Vice
President at LXRepair.
Mrs. Anne Jacquet, PhD., is appointed Medical
DirectorPhD. in pharmacology (Mediterranean University,
Marseille) and Doctor of Pharmacy (University of Nantes) Anne
Jacquet (46), has over 15 years of experience in preclinical and
clinical research in the field of cardiovascular disease and
oncology. She also has an in-depth knowledge of regulatory
procedures in Europe and the United States.
Aaron Bensimon, Genomic Vision’s co-founder and Chairman,
concludes: “We are delighted with the arrival of another three
acknowledged experts within our senior management team. Their
complementarity will be extremely beneficial for Genomic Vision
from both a corporate development perspective, through new
partnerships, and a clinical perspective, with a number of ongoing
key studies.”
Upcoming financial publication
- Annual Revenue for 2015, Monday,
January 18, 2016* (after trading)
* indicative date, which may be subject to
change
ABOUT GENOMIC VISIONFounded in 2004, Genomic Vision is a
molecular diagnostics company that specializes in the development
of diagnostic tests for genetic diseases and cancers based on
molecular combing. Using this innovative technology that allows the
direct visualization of individual DNA molecules, Genomic Vision
detects quantitative and qualitative variations in the genome that
are at the origin of numerous serious pathologies. The Company is
developing a solid portfolio of tests that initially target breast
and colon cancers. Since 2013, the Company has marketed the
CombHelix FSHD test for identifying facioscapulohumeral dystrophy
(FSHD), a myopathy that is difficult to detect. It is marketed in
the United States through a strategic alliance with Quest
Diagnostics, the American leader in diagnostic laboratory tests,
and in France directly by the Company. Genomic Vision has been
listed on Compartment C of Euronext Paris since April 2014.
ABOUT MOLECULAR COMBINGDNA molecular combing technology
significantly improves the structural and functional analysis of
DNA molecules. DNA fibers are stretched over glass slides, as if
"combed", and uniformly aligned over the entire surface. It is then
possible to identify genetic anomalies by locating specific genes
or sequences in the patient's genome using genetic markers, a
technique developed by Genomic Vision and patented under the name
Genomic Morse Code. This exploration of the entire genome at high
resolution via a simple analysis enables the direct visualization
of genetic anomalies that are undetectable by other
technologies.
For further information, please go to: www.genomicvision.com
Member of CAC® Mid & Small, CAC®
All-Tradable and EnterNext© PEA-PME 150 indexes
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160111006208/en/
Genomic VisionAaron BensimonCo-founder, Chairman &
CEOTel.: +33 1 49 08 07
50investisseurs@genomicvision.comorLHAInvestor Relations
USAnne Marie Fields, SVPTel.:
212-838-3777afields@lhai.comorNewCapInvestor Relations
/Strategic CommunicationsDušan Orešanský / Emmanuel HuynhTel.: +33
1 44 71 94 92gv@newcap.fr
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024